[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366844-105":59,"doc-detail-366844-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","editorial-for-the-special-issue-current-research-on-cancer-biology-and-therapeutics-third-edition","Editorial for the Special Issue “Current Research on Cancer Biology and Therapeutics: Third Edition”","","Editorial introducing the third edition of a special issue focused on current cancer biology and therapeutics. It summarizes contributions spanning bispecific antibodies for solid tumors, teratoma development and the seminoma microenvironment, neuroblastoma and peptidergic systems, and hepatocellular carcinoma, alongside synthesis of novel podophyllotoxin–benzothiazole congeners and studies of aryl hydrocarbon receptor and STAT3 in chemical carcinogenesis. It highlights review findings on approved bispecific therapies, mechanisms, toxicity, tissue penetration, resistance, and prioritizes future research directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/editorial-for-the-special-issue-current-research-on-cancer-biology-and-therapeutics-third-edition/366844/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/editorial-for-the-special-issue-current-research-on-cancer-biology-and-therapeutics-third-edition/366844.png","ImageObject",300,407,{"name":92,"@type":93},"RuangKosong","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What major research themes are covered in this third edition editorial?","Question",{"text":112,"@type":113},"The editorial highlights bispecific antibodies for solid tumors, teratoma development and immune infiltration, seminoma microenvironment mechanisms, plus studies spanning neuroblastoma/peptidergic systems and hepatocellular carcinoma, with additional chemistry and signaling-pathway contributions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do bispecific antibodies work against solid tumors, according to the editorial?",{"text":117,"@type":113},"They can bind two epitopes (same antigen or different antigens) while enabling immune cells to kill tumor cells, with blockade of relevant signaling pathways; the editorial also discusses mechanisms, toxicity, tissue penetration, and resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"What future research directions does the editorial prioritize?",{"text":121,"@type":113},"It emphasizes prioritizing combinations of bispecific antibody therapies, multispecific strategies targeting multiple antigens, and combinations of tyrosine kinase inhibitors or chemotherapy with bispecific antibodies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366844,1791387682,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090883219,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Editorial  \nEditorial for the Special Issue “Current Research on Cancer Biology and Therapeutics: Third Edition”  \nRafael Coveñas 1,2  \nReceived: 22 October 2025  \nAccepted: 25 November 2025  \nPublished: 28 November 2025  \nCitation: Coveñas, R. Editorial for the Special Issue “Current Research on Cancer Biology and Therapeutics: Third Edition”. Int. J. Mol. Sci. 2025, 26, 11537. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms262311537  \nCopyright: © 2025 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neuroscience of Castilla y León (INCYL), University of Salamanca, c/ Pintor Fernando Gallego 1, 37007 Salamanca, Spain; [covenas@usal.es](covenas@usal.es); Tel.: +34-923-294-400 (ext. 1856)  \n2 Group GIR USAL: BMD (Bases Moleculares del Desarrollo), University of Salamanca, 37007 Salamanca, Spain  \nIn the third edition of this Special Issue, the participating researchers focused their studies on bispecific antibodies against solid tumors [contribution 1], teratoma development [contribution 2], the seminoma microenvironment [contribution 3], neuroblastoma and peptidergic systems [contribution 4], hepatocellular carcinoma [contribution 5], the synthesis of novel podophyllotoxin–benzothiazole congeners for use as anticancer agents [contribution 6], the effects of podophyllotoxin derivatives on non-cancerous diseases [contribution 7], and the involvement of the aryl hydrocarbon receptor and the signal transducer and activator of transcription 3 in chemical carcinogenesis [contribution 8] .  \nKhine Swe Shan’s group from the Division of Hematology and Oncology (Memorial Health Care, Pembroke Pines, FL, USA) has reviewed the use of bispecific antibodies against solid tumors [contribution 1] . These antibodies can simultaneously bind to two different epitopes of the same antigen or different antigens, provided that immune cells kill tumor cells and there is a blockade of the signaling pathways. The bispecific antibodies zenocutuzumab, zanidatamab, tebentafusp, tarlatamab, and amivantamab have been approved by the U.S. Food and Drug Administration for use in treating solid tumors, whereas ivonescimab and cadonilimab have been approved in the People’s Republic of China. In this extensive review, the authors discuss the advances and challenges pertaining to the application of bispecific antibodies to solid tumors; their mechanisms of action, toxicity, and tissue penetration; and resistance therapy. They also report the available data on the bispecific antibodies currently approved in clinical practice and discuss the ones currently being investigated (most of them in early phase I and II trials), targeting, for example, the human epidermal growth factor receptor 2, the prostate-specific membrane antigen, claudin 18.2, the carcinoembryonic antigen, the epithelial cell adhesion molecule, glyican-3, the human leukocyte antigen G, and immune checkpoint molecules. In addition, they establish the future lines of research that should be prioritized [contribution 1], includingthe combination of bispecific antibody therapies, multi-specific strategies targeting multiple antigens at the same time, or the combination of tyrosine kinase inhibitors or chemotherapy with bispecific antibodies.  \nHolger M. Reichardt et al. from the Institute for Cellular and Molecular Immunology (University Medical Center Göttingen, Germany) studied the infiltration of immune cells in the 129.MOLF-Chr19 teratoma experimental mouse model [contribution 2] . Teratoma, a differentiated type of testicular germ cell tumor, is the most common solid tumor in young men and is characterized by inflammatory inf","cbCaib91JMkfvzbq","https://ap.wps.com/l/cbCaib91JMkfvzbq","pdf",174244,"English","# Contributions in the Third Edition\n## Bispecific antibodies for solid tumors\n## Teratoma development and immune infiltration\n## Seminoma microenvironment and cytokine/cell-contact signaling","[{\"question\":\"What major research themes are covered in this third edition editorial?\",\"answer\":\"The editorial highlights bispecific antibodies for solid tumors, teratoma development and immune infiltration, seminoma microenvironment mechanisms, plus studies spanning neuroblastoma/peptidergic systems and hepatocellular carcinoma, with additional chemistry and signaling-pathway contributions.\"},{\"question\":\"How do bispecific antibodies work against solid tumors, according to the editorial?\",\"answer\":\"They can bind two epitopes (same antigen or different antigens) while enabling immune cells to kill tumor cells, with blockade of relevant signaling pathways; the editorial also discusses mechanisms, toxicity, tissue penetration, and resistance.\"},{\"question\":\"What future research directions does the editorial prioritize?\",\"answer\":\"It emphasizes prioritizing combinations of bispecific antibody therapies, multispecific strategies targeting multiple antigens, and combinations of tyrosine kinase inhibitors or chemotherapy with bispecific antibodies.\"}]","Editorial for the Special Issue “Current Research on Cancer Biology and Therapeutics: Third Edition” | PDF",1790167881,15,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62b612b95fb540bc36c6eecfa09dfd20.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d0b311f18c4b51a19fcad253e2374bff.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c4d7909b6341e46f79fffe7f9cce6c5.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1434601095f63951cb45030dbd96a432.webp",980,1385]